These effects were shown for both ER+ and ER− BCs (Hastert et al., 2013; McKenzie et al., 2015) and with increased penetration of BRCA2 (1920–2000) and BC prevalence in the general population, together suggesting that all BC types may potentially benefit from the above preventive measures (Tryggvadottir et al., 2006). The gene discussed is BRCA2; the disease is breast cancer.